[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100338413":3},{"organization":4,"armGroups":7,"interventions":58,"overallOfficials":88,"centralContacts":92,"locations":97,"responsibleParty":362,"collaborators":75,"id":364,"slug":365,"hasResults":366,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":366,"sex":372,"minAge":373,"maxAge":75,"enrollmentInfo":374,"targetDuration":75,"studyType":377,"phases":378,"briefSummary":381,"conditions":382,"keywords":387,"overallStatus":100,"whyStopped":75,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":405},{"fullName":5,"class":6},"Immatics US, Inc.","INDUSTRY",[8,15,19,24,29,32,37,41,45,49,52,55],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation A (closed to enrollment)","EXPERIMENTAL","Dose escalation of IMA203",[13,14],"Biological: IMA203 Product","Device: IMADetect®",{"label":16,"type":10,"description":17,"interventionNames":18},"Extension Cohort A","IMA203 at RP2D",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Extension Cohort B (closed to enrollment)","IMA203 at RP2D + nivolumab",[13,23],"Drug: Nivolumab",{"label":25,"type":10,"description":26,"interventionNames":27},"Extension Cohort AA","IMA203 at final RP2D (flat dose)",[28,14],"Biological: IMA203 product- flat dose",{"label":30,"type":10,"description":17,"interventionNames":31},"Uveal Melanoma",[13,14],{"label":33,"type":10,"description":34,"interventionNames":35},"Dose Escalation B","Dose escalation of IMA203CD8",[36,14],"Biological: IMA203CD8 Product",{"label":38,"type":10,"description":39,"interventionNames":40},"Extension Cohort C","IMA203CD8 at dose levels confirmed to be safe",[36,14],{"label":42,"type":10,"description":43,"interventionNames":44},"Extension Cohort D","IMA203CD8 at dose levels confirmed to be safe; without IL-2",[36,14],{"label":46,"type":10,"description":47,"interventionNames":48},"Ovarian","IMA203CD8 monotherapy at dose levels confirmed to be safe",[36,14],{"label":50,"type":10,"description":47,"interventionNames":51},"Endometrial",[36,14],{"label":53,"type":10,"description":47,"interventionNames":54},"Head and Neck, Lung, and Triple Negative Breast Cancer",[36,14],{"label":56,"type":10,"description":47,"interventionNames":57},"Rare Cancers",[36,14],[59,67,72,76,83],{"type":60,"name":61,"description":62,"armGroupLabels":63,"otherNames":64},"BIOLOGICAL","IMA203 Product","The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula",[9,16,20,30],[65,66],"anzutresgene autoleucel","anzu-cel",{"type":60,"name":68,"description":69,"armGroupLabels":70,"otherNames":71},"IMA203 product- flat dose","The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells",[25],[65,66],{"type":60,"name":73,"description":62,"armGroupLabels":74,"otherNames":75},"IMA203CD8 Product",[33,50,38,42,53,46,56],null,{"type":77,"name":78,"description":79,"armGroupLabels":80,"otherNames":81},"DRUG","Nivolumab","Nivolumab will be given post IMA203\u002FIMA203CD8 infusion, after hematologic recovery is achieved. Clinical supply provided by Bristol Myers Squibb.",[20],[82],"Opdivo®",{"type":84,"name":85,"description":86,"armGroupLabels":87,"otherNames":75},"DEVICE","IMADetect®","IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and\u002For refractory solid cancers who might be eligible for enrollment in Immatics clinical trials.",[9,33,50,16,25,38,42,53,46,56,30],[89],{"name":90,"affiliation":5,"role":91},"Cedrik Britten, M.D.","STUDY_DIRECTOR",[93],{"name":5,"role":94,"phone":95,"phoneExt":75,"email":96},"CONTACT","+1 346 204-5400","ctgovinquiries@immatics.com",[98,116,130,144,157,171,185,199,213,224,237,253,269,283,295,305,314,324,334,344,353],{"facility":99,"status":100,"city":101,"state":102,"zip":103,"country":104,"countryCode":105,"cosmosGeoPoint":106,"geoPoint":111,"contacts":112},"Stanford Cancer Institute","RECRUITING","Stanford","California","94305","United States","US",{"type":107,"coordinates":108},"Point",[109,110],-122.16608,37.42411,{"lat":110,"lon":109},[113],{"name":114,"role":94,"phone":75,"phoneExt":75,"email":115},"Allison Warner, MD","allison.betof@stanford.edu",{"facility":117,"status":100,"city":118,"state":119,"zip":120,"country":104,"countryCode":105,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"University of Colorado, Anschutz Medical Campus","Aurora","Colorado","80045",{"type":107,"coordinates":122},[123,124],-104.83192,39.72943,{"lat":124,"lon":123},[127],{"name":128,"role":94,"phone":129,"phoneExt":75,"email":75},"Sapna Patel, MD","720-848-0000",{"facility":131,"status":100,"city":132,"state":133,"zip":134,"country":104,"countryCode":105,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"University of Miami Hospital and Clinics","Miami","Florida","33136",{"type":107,"coordinates":136},[137,138],-80.19366,25.77427,{"lat":138,"lon":137},[141],{"name":75,"role":94,"phone":142,"phoneExt":75,"email":143},"305-243-2647","CRSCutaneous@miami.edu",{"facility":145,"status":100,"city":146,"state":147,"zip":148,"country":104,"countryCode":105,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"University of Chicago Medical Center","Chicago","Illinois","60637",{"type":107,"coordinates":150},[151,152],-87.65005,41.85003,{"lat":152,"lon":151},[155],{"name":156,"role":94,"phone":75,"phoneExt":75,"email":75},"Katherine Kurnit, MD",{"facility":158,"status":100,"city":159,"state":160,"zip":161,"country":104,"countryCode":105,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":107,"coordinates":163},[164,165],-71.05977,42.35843,{"lat":165,"lon":164},[168],{"name":169,"role":94,"phone":170,"phoneExt":75,"email":75},"Oldadapo O. Yeku, MD. PhD","617-643-6158",{"facility":172,"status":100,"city":173,"state":173,"zip":174,"country":104,"countryCode":105,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":107,"coordinates":176},[177,178],-74.00597,40.71427,{"lat":178,"lon":177},[181],{"name":182,"role":94,"phone":183,"phoneExt":75,"email":184},"Alexander Shoushtari, MD","646-888-4161","shoushta@mskcc.org",{"facility":186,"status":100,"city":187,"state":188,"zip":189,"country":104,"countryCode":105,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run","Columbus","Ohio","43026",{"type":107,"coordinates":191},[192,193],-82.99879,39.96118,{"lat":193,"lon":192},[196],{"name":197,"role":94,"phone":75,"phoneExt":75,"email":198},"Casey Cosgrove, MD","Casey.Cosgrove@osumc.edu",{"facility":200,"status":100,"city":201,"state":202,"zip":203,"country":104,"countryCode":105,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"University of Pennsylvania, Perelamn Center for Advanced Medicine","Philadelphia","Pennsylvania","19104",{"type":107,"coordinates":205},[206,207],-75.16362,39.95238,{"lat":207,"lon":206},[210],{"name":211,"role":94,"phone":75,"phoneExt":75,"email":212},"Janos Tanyi, MD, PhD","Janos.Tanyi@pennmedicine.upenn.edu",{"facility":214,"status":100,"city":201,"state":202,"zip":215,"country":104,"countryCode":105,"cosmosGeoPoint":216,"geoPoint":218,"contacts":219},"Thomas Jefferson University, Honickman Center","19107",{"type":107,"coordinates":217},[206,207],{"lat":207,"lon":206},[220],{"name":221,"role":94,"phone":222,"phoneExt":75,"email":223},"Rino Seedor, MD","215-847-7409","Rino.Seedor@jefferson.edu",{"facility":225,"status":100,"city":201,"state":202,"zip":226,"country":104,"countryCode":105,"cosmosGeoPoint":227,"geoPoint":229,"contacts":230},"Fox Chase Cancer Center","19111",{"type":107,"coordinates":228},[206,207],{"lat":207,"lon":206},[231,234],{"name":232,"role":94,"phone":75,"phoneExt":75,"email":233},"Anthony Olszanski, MD, RPh","Anthony.Olszanski@fccc.edu",{"name":235,"role":236,"phone":75,"phoneExt":75,"email":75},"Anthony Olszanski, MD","PRINCIPAL_INVESTIGATOR",{"facility":238,"status":100,"city":239,"state":202,"zip":240,"country":104,"countryCode":105,"cosmosGeoPoint":241,"geoPoint":245,"contacts":246},"University of Pittsburgh Medical Center","Pittsburgh","15232",{"type":107,"coordinates":242},[243,244],-79.99589,40.44062,{"lat":244,"lon":243},[247,251],{"name":248,"role":94,"phone":249,"phoneExt":75,"email":250},"Diwakar Davar, M.D.","412-623-7368","davard@upmc.edu",{"name":252,"role":236,"phone":75,"phoneExt":75,"email":75},"Jason Luke, M.D.",{"facility":254,"status":100,"city":255,"state":256,"zip":257,"country":104,"countryCode":105,"cosmosGeoPoint":258,"geoPoint":262,"contacts":263},"University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":107,"coordinates":259},[260,261],-95.36327,29.76328,{"lat":261,"lon":260},[264,268],{"name":265,"role":94,"phone":266,"phoneExt":75,"email":267},"Dejka M Araujo, M.D.","713-792-3626","daraujo@mdanderson.org",{"name":265,"role":236,"phone":75,"phoneExt":75,"email":75},{"facility":270,"status":100,"city":271,"state":272,"zip":273,"country":104,"countryCode":105,"cosmosGeoPoint":274,"geoPoint":278,"contacts":279},"Fred Hutchinson Cancer Center","Seattle","Washington","98109",{"type":107,"coordinates":275},[276,277],-122.33207,47.60621,{"lat":277,"lon":276},[280],{"name":281,"role":94,"phone":75,"phoneExt":75,"email":282},"Sylvia Lee, MD","leesm@uw.edu",{"facility":284,"status":100,"city":285,"state":286,"zip":287,"country":288,"countryCode":289,"cosmosGeoPoint":290,"geoPoint":294,"contacts":75},"Universitätsklinikum Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT)","Heidelberg","Baden-Wurttemberg","69120","Germany","DE",{"type":107,"coordinates":291},[292,293],8.69079,49.40768,{"lat":293,"lon":292},{"facility":296,"status":100,"city":297,"state":298,"zip":299,"country":288,"countryCode":289,"cosmosGeoPoint":300,"geoPoint":304,"contacts":75},"Klinikum rechts der Isar der Technischen Universität München","Munich","Bavaria","81675",{"type":107,"coordinates":301},[302,303],11.57549,48.13743,{"lat":303,"lon":302},{"facility":306,"status":100,"city":307,"state":298,"zip":308,"country":288,"countryCode":289,"cosmosGeoPoint":309,"geoPoint":313,"contacts":75},"Universitätsklinikum Würzburg","Würzburg","97080",{"type":107,"coordinates":310},[311,312],9.95121,49.79391,{"lat":312,"lon":311},{"facility":315,"status":100,"city":316,"state":317,"zip":318,"country":288,"countryCode":289,"cosmosGeoPoint":319,"geoPoint":323,"contacts":75},"Universitätsklinikum Bonn - Medizinische Klinik III","Bonn","North Rhine-Westphalia","53127",{"type":107,"coordinates":320},[321,322],7.09549,50.73438,{"lat":322,"lon":321},{"facility":325,"status":100,"city":326,"state":327,"zip":328,"country":288,"countryCode":289,"cosmosGeoPoint":329,"geoPoint":333,"contacts":75},"Universitätsmedizin der Johannes Gutenberg-Universität Mainz","Mainz","Rhineland-Palatinate","55131",{"type":107,"coordinates":330},[331,332],8.28008,49.98185,{"lat":332,"lon":331},{"facility":335,"status":100,"city":336,"state":337,"zip":338,"country":288,"countryCode":289,"cosmosGeoPoint":339,"geoPoint":343,"contacts":75},"Universitätsklinikum C.-G.-Carus Dresden","Dresden","Saxony","01307",{"type":107,"coordinates":340},[341,342],13.73832,51.05089,{"lat":342,"lon":341},{"facility":345,"status":100,"city":346,"state":75,"zip":347,"country":288,"countryCode":289,"cosmosGeoPoint":348,"geoPoint":352,"contacts":75},"Charité Benjamin Franklin - Klinik für Hämatologie und Onkologie","Berlin","12203",{"type":107,"coordinates":349},[350,351],13.41053,52.52437,{"lat":351,"lon":350},{"facility":354,"status":100,"city":355,"state":75,"zip":356,"country":288,"countryCode":289,"cosmosGeoPoint":357,"geoPoint":361,"contacts":75},"Universitätsklinikum Hamburg-Eppendorf","Hamburg","20246",{"type":107,"coordinates":358},[359,360],9.99302,53.55073,{"lat":360,"lon":359},{"type":363,"investigatorFullName":75,"investigatorTitle":75,"investigatorAffiliation":75,"oldNameTitle":75,"oldOrganization":75},"SPONSOR","100338413","phase-1-actengine-ima203ima203cd8-as-monotherapy-or-in-combination-with-nivolumab-in-recurrent-andor-refractory-solid-tumors-100338413",false,"NCT03686124","ACTengine® IMA203\u002FIMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and\u002For Refractory Solid Tumors","Phase 1\u002F2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer\u002FGermline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and\u002For Refractory Solid Tumors","ACTengine","Inclusion Criteria:\n\n* Patients must have recurrent\u002Fprogressing and\u002For refractory solid tumors and must have received or not be eligible for all available indicated standard of care treatment.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* HLA-A\\*02:01 positive\n* For patients with ovarian\u002Ffallopian tube cancer only: Patients must have confirmed diagnosis of high-grade serous or endometrioid epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer.\n* For patients with endometrial carcinoma only: Patients must have a histologically confirmed diagnosis of recurrent or persistent endometrial carcinoma.\n* Measurable disease according to RECIST 1.1\n* Adequate selected organ function per protocol\n* Patient's tumor must express tumor antigen by \"IMADetect® RT-qPCR. Retrospective testing will be required for patients that qualify.\n* Life expectancy more than 5 months\n* Female patient of childbearing potential must use adequate contraception prior to study entry until 12 months after the infusion of IMA203\u002FIMA203CD8\n* Male patient must agree to use effective contraception or be abstinent while on study and for 6 months after the infusion of IMA203\u002FIMA203CD8\n* The patient must have recovered from any side effects of prior therapy to Grade 1 or lower prior to lymphodepletion.\n\nExclusion Criteria:\n\n* History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years\n* Pregnant or breastfeeding\n* Serious autoimmune disease Note: At the discretion of the investigator, these patients may be included if their disease is well controlled without the use of immunosuppressive agents.\n* History of cardiac conditions as per protocol\n* Prior stem cell transplantation or solid organ transplantation\n* Concurrent severe and\u002For uncontrolled medical disease that could compromise participation in the study\n* History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician\n* Positive for HIV infection or with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.\n* Patients with LDH greater than 2.0-fold ULN.\n* Any condition contraindicating leukapheresis, lymphodepletion, low-dose IL-2, and\u002For IMA203\u002FIMA203CD8 treatment\n* Patients with active brain metastases\n* Concurrent treatment in another clinical trial.\n* For nivolumab treatment, patients must not have a history of severe immune-related toxicities, defined as any Grade 3 or 4 toxicities related to prior PD1\u002FPD-L1 inhibitor therapy (e.g., atezolizumab, pembrolizumab or nivolumab etc.).\n\nOther protocol defined inclusion\u002Fexclusion criteria could apply","ALL","18 Years",{"count":375,"type":376},375,"ESTIMATED","INTERVENTIONAL",[379,380],"PHASE1","PHASE2","The study's purpose is to establish the safety and tolerability of IMA203\u002FIMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).",[383,384,385,386],"Refractory Cancer","Recurrent Cancer","Solid Tumor, Adult","Cancer",[388,389,390,391,392,393,394,395],"T-cell therapy","immunotherapy","Melanoma (Skin)","Melanoma, Uveal","Ovarian Carcinoma","Uterine Carcinoma","Uterine Carcinosarcoma","Immatics","2026-05-12",{"date":398,"type":399},"2026-05-13","ACTUAL",{"date":401,"type":399},"2019-05-14",{"date":403,"type":376},"2032-06",{"name":5,"class":6},21]